A

Alnylam Pharmaceuticals

Develops RNAi-based therapies for genetic diseases

Senior Director - Toxicology

Regulatory & Quality (Life Sciences)Confirmed live in the last 24 hours
Full-timeCambridge, MA, USA$222.8k - $314k

About the Job

Requirements

  • A PhD in Toxicology or an advanced degree in a related scientific discipline is required; board certification is ideal.
  • At least 12 years of relevant pharmaceutical or biotechnology industry experience supporting nonclinical drug development from discovery through registration.
  • Ability to independently lead complex development programs and influence scientific, program, and portfolio decisions in a matrixed organization.
  • Deep expertise in nonclinical safety assessment across the drug development lifecycle, including developing and executing strategies supporting global regulatory submissions.
  • Extensive knowledge of applicable global regulatory guidance and standards, including FDA GLP, OECD, and ICH requirements.
  • Experience selecting, engaging, and providing scientific oversight of contract research organizations.
  • Ability to integrate and interpret complex data across toxicology, pathology, DMPK, safety pharmacology, and related disciplines, and to develop solutions when results are ambiguous.
  • Ability to communicate complex scientific and regulatory topics clearly to project teams, senior leaders, external partners, and regulatory authorities in writing, verbally, and through presentations.
  • Ability to guide, mentor, and develop scientists.

Responsibilities

  • Lead integrated, phase-appropriate nonclinical safety strategies across multiple development programs or a therapeutic area or platform, working independently and, where applicable, through direct reports.
  • Serve as the senior Toxicology and early development representative on cross-functional teams, providing scientific and strategic leadership for development candidates from discovery through registration.
  • Serve as a recognized scientific resource within Toxicology and across R&D, guiding the evaluation, integration, and communication of nonclinical risks, mitigation strategies, and potential clinical relevance.
  • Provide strategic direction across nonclinical safety assessment, including investigative and general toxicology, safety pharmacology, developmental and reproductive toxicology, and carcinogenicity evaluations, as appropriate.
  • Provide scientific leadership for the design, conduct, interpretation, and reporting of GLP and non-GLP toxicology studies conducted at contract research organizations, in partnership with the study monitoring group.
  • Maintain current knowledge of industry trends and global regulatory requirements to support scientifically rigorous nonclinical safety packages for regulatory submissions, including INDs, CTAs, NDAs, BLAs, and MAAs.
  • Represent Toxicology in interactions with global health authorities, as appropriate.
  • Translate complex nonclinical findings into clear scientific and business considerations that inform program and portfolio decisions.
  • Recruit, onboard, mentor, and develop scientific talent, as appropriate, while fostering an inclusive, collaborative, and high-performing environment.
  • Partner with Early Development and Toxicology leadership to strengthen scientific practices, policies, and procedures governing toxicology research.
  • Maintain clear communication with leadership regarding program activities, scientific risks, resource considerations, and team priorities.

Desired Qualifications

  • Direct people-management experience.
  • Experience representing Toxicology in global health-authority interactions.
  • Broad experience across multiple therapeutic areas, development programs, or technology platforms.

About the Company

Alnylam Pharmaceuticals

Develops RNAi-based therapies for genetic diseases

Alnylam Pharmaceuticals develops RNA interference (RNAi) therapeutics to silence disease-causing genes, aiming to treat rare genetic disorders. Its products work by using RNA molecules that block gene expression, reducing the impact of specific genetic diseases. The company differentiates itself by concentrating on RNAi-based drugs for rare diseases and by building a pipeline through large clinical programs and strategic partnerships, such as commercialization deals in the Gulf States and collaborations with investors. Revenue comes from approved drug sales, licensing agreements, strategic collaborations, and related services like genetic testing and counseling. The company’s goal is to advance and commercialize RNAi therapies to improve outcomes for patients with genetic disorders, expanding its portfolio through partnerships and investments.

Company size
1,001-5,000
Company stage
IPO
Headquarters
Cambridge, MA
Founded
2002

Recently Posted Jobs

Explore more opportunities at Alnylam Pharmaceuticals

See more jobs